| Product Code: ETC8253653 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview |
3.1 Mauritius Country Macro Economic Indicators |
3.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, 2021 & 2031F |
3.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Industry Life Cycle |
3.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Porter's Five Forces |
3.5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.7 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about chronic inflammatory demyelinating polyneuropathy (CIDP) among healthcare professionals and patients |
4.2.2 Technological advancements in the diagnosis and treatment of CIDP |
4.2.3 Growing prevalence of autoimmune disorders in Mauritius leading to a higher incidence of CIDP |
4.3 Market Restraints |
4.3.1 High cost of CIDP treatment options and limited healthcare coverage for specialized therapies |
4.3.2 Lack of skilled healthcare professionals specializing in CIDP management in Mauritius |
4.3.3 Regulatory challenges and delays in the approval of new CIDP treatments in the market |
5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends |
6 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Types |
6.1 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous Immunoglobulin, 2021- 2031F |
6.1.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.1.5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Plasmapheresis, 2021- 2031F |
6.1.6 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Physiotherapy, 2021- 2031F |
6.1.7 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Diagnosis |
6.2.1 Overview and Analysis |
6.2.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Electrodiagnostic Testing, 2021- 2031F |
6.2.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Nerve Conduction, 2021- 2031F |
6.2.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By EMG, 2021- 2031F |
6.2.5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Spinal Fluid Analysis, 2021- 2031F |
6.2.6 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.3.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.5.5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenues & Volume, By Others, 2021- 2031F |
7 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Import-Export Trade Statistics |
7.1 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Export to Major Countries |
7.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Imports from Major Countries |
8 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Key Performance Indicators |
8.1 Patient-reported outcomes and quality of life improvements post-treatment |
8.2 Time to diagnosis and initiation of CIDP treatment |
8.3 Number of clinical trials and research studies focused on CIDP in Mauritius |
9 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Opportunity Assessment |
9.1 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.3 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Competitive Landscape |
10.1 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue Share, By Companies, 2024 |
10.2 Mauritius Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here